Dina Chaya, PhD
Partner, NeoMed Management
Dina joined NeoMed in 2009. She manages NeoMed’s funds and assists with and advises on new investments for Omega Fund V.
Dina has been investing in the private equity and venture capital healthcare industry since 2001. Previously at 3i in London and Index Ventures in Geneva, her recent investments including Attenua, Oxular, TopiVert, Wilson Therapeutics, EUSA Pharma, Endosense and Novexel. Dina is a CFA charterholder and holds a Ph.D. degree in Molecular and Cellular Biology from Paris VI University, France. She carried out postdoctoral research at Brown University, Providence, US, and at the Fox Chase Cancer Centre, Philadelphia, US.